HIGHLIGHTS
- who: Daisuke Watanabe from the Department of Palliative Medicine, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan have published the research work: Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis, in the Journal: (JOURNAL)
- what: This study explored the effect of once-yearly zoledronic acid 5 mg (ZOL 5 mg) on bone mineral density (BMD) and new vertebral fractures (VFs) in M0CSPC patients with coexisting osteoporosis before starting ADT. In this study, the values of renal function markers . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.